Publication | Closed Access

A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C

OncologyPancreatic CancerMedicineAntibody-drug ConjugatePathologyPhase Ii StudyCancer TreatmentPharmacologyRadiation OncologyGuanylyl Cyclase CCancer Research